GOSH statement on new personalised therapy for children with cancer

5 Sep 2018, 3:56 p.m.

Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH)

Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH), says:

“GOSH welcomes the exciting announcement that for children with Acute Lymphoblastic Leukaemia (ALL), CAR-T cell therapy will be made available on the NHS.

“This is a landmark moment in the treatment of childhood cancer in the UK. GOSH has been at the forefront of cutting edge personalised CAR-T therapy treatment for a number of years developing similar CAR-T therapies for children with ALL. Since 2012, we have treated over 25 patients from all over the UK with CAR-T therapies. In 2015, we treated the first patient worldwide with gene edited  “universal” CAR-T cells. We are continuing to work on improving CAR-T cell therapy including using “next generation” CAR-T cells to further reduce the chance of relapse.

“We believe that personalised cell therapy treatments, which allow us to tailor treatments to individual patients, can be the silver bullet, offering a real chance of success for children who have run out of all other options.”

Professor Amrolia is also a NIHR Research Professor of Transplantation Immunology at UCL Great Ormond Street Institute of Child Health.

GOSH poem celebrates 75 years of the NHS

GOSH staff have shared how much working in the NHS means to them in a new poem to mark the 75-year anniversary of the service.

GOSH patients take part in organ donation campaign

GOSH patients are taking part in a campaign to raise awareness about paediatric organ donation.

GOSH patient celebrates 35-year anniversary of heart and lung transplant

A patient has celebrated the 35th anniversary of their heart and lung transplant – making them GOSH’s longest surviving recipient of this kind of transplant.

Clinical trial results give new hope for children with rare brain tumours

Researchers who are searching for better treatments for an incredibly rare type of brain tumour have published successful results from the latest rounds of clinical trials.